Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-M...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2016-01, Vol.2, p.2055217316630008-2055217316630008 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2055217316630008 |
|---|---|
| container_issue | |
| container_start_page | 2055217316630008 |
| container_title | Multiple sclerosis journal - experimental, translational and clinical |
| container_volume | 2 |
| creator | Salmen, A. von Ahsen, N. Trampe, A.K. Hoepner, R. Plavina, T. Subramanyam, M. Kuesters, G. Gold, R. Chan, A. |
| description | Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2–2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8–17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1–3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0–3.4), n = 298, p = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3–90.4) increased PML risk (p = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation. |
| doi_str_mv | 10.1177/2055217316630008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5433507</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_2055217316630008</sage_id><sourcerecordid>1909220409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3778-c2d481bcb74a4655d978802de26b6937e3e3e5b43c05fbd6a1afa66e26b527003</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhq2qqLsC7j2hSFx6CYzt2E4uSNWK8qGVuECvluM4u4YkDnaCuv8eh4UtXamyZI9nnnln7EHoO4YzjIU4J8AYwYJizikA5F_QfHKlk-_rJ3uGjkN4jARmPDrxNzQjOQchcDZHfum6lR3GynaqSVTcNsGExNXRHmx6u_j9ZpSu2iS2q8yfpHY-8TY8JSpEMrSmGya8927l492-mKQdm8HWTkfFxoxPznTa9GvVuF4N680ROqhVE8zx-3mIHn5d3i-u0-Xd1c3i5zLVVIg81aTKclzqUmQq44xVhchzIJUhvOQFFYbGxcqMamB1WXGFVa04n8KMCAB6iC62uv1YtqbSsVGvGtl72yq_kU5Z-W-ks2u5ci-SZZQyEFHgx7uAd8-jCYNsbdCmaVRn3BgkLqAgBDIoInq6hz660cffDJLQjFCgAnCkYEtp70Lwpt41g0FOM5X7M40pJ58fsUv4mGAE0i0Q1Mr8rfpfwVch1aru</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2342303701</pqid></control><display><type>article</type><title>Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Salmen, A. ; von Ahsen, N. ; Trampe, A.K. ; Hoepner, R. ; Plavina, T. ; Subramanyam, M. ; Kuesters, G. ; Gold, R. ; Chan, A.</creator><creatorcontrib>Salmen, A. ; von Ahsen, N. ; Trampe, A.K. ; Hoepner, R. ; Plavina, T. ; Subramanyam, M. ; Kuesters, G. ; Gold, R. ; Chan, A.</creatorcontrib><description>Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2–2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8–17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1–3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0–3.4), n = 298, p = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3–90.4) increased PML risk (p = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation.</description><identifier>ISSN: 2055-2173</identifier><identifier>EISSN: 2055-2173</identifier><identifier>DOI: 10.1177/2055217316630008</identifier><identifier>PMID: 28607714</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Encephalitis ; Immunotherapy ; Monoclonal antibodies ; Risk assessment ; Short Report ; Viral infections</subject><ispartof>Multiple sclerosis journal - experimental, translational and clinical, 2016-01, Vol.2, p.2055217316630008-2055217316630008</ispartof><rights>The Author(s) 2016</rights><rights>The Author(s) 2016. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2016 2016 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3778-c2d481bcb74a4655d978802de26b6937e3e3e5b43c05fbd6a1afa66e26b527003</citedby><cites>FETCH-LOGICAL-c3778-c2d481bcb74a4655d978802de26b6937e3e3e5b43c05fbd6a1afa66e26b527003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433507/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433507/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28607714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salmen, A.</creatorcontrib><creatorcontrib>von Ahsen, N.</creatorcontrib><creatorcontrib>Trampe, A.K.</creatorcontrib><creatorcontrib>Hoepner, R.</creatorcontrib><creatorcontrib>Plavina, T.</creatorcontrib><creatorcontrib>Subramanyam, M.</creatorcontrib><creatorcontrib>Kuesters, G.</creatorcontrib><creatorcontrib>Gold, R.</creatorcontrib><creatorcontrib>Chan, A.</creatorcontrib><title>Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy</title><title>Multiple sclerosis journal - experimental, translational and clinical</title><addtitle>Mult Scler J Exp Transl Clin</addtitle><description>Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2–2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8–17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1–3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0–3.4), n = 298, p = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3–90.4) increased PML risk (p = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation.</description><subject>Encephalitis</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>Risk assessment</subject><subject>Short Report</subject><subject>Viral infections</subject><issn>2055-2173</issn><issn>2055-2173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU1P3DAQhq2qqLsC7j2hSFx6CYzt2E4uSNWK8qGVuECvluM4u4YkDnaCuv8eh4UtXamyZI9nnnln7EHoO4YzjIU4J8AYwYJizikA5F_QfHKlk-_rJ3uGjkN4jARmPDrxNzQjOQchcDZHfum6lR3GynaqSVTcNsGExNXRHmx6u_j9ZpSu2iS2q8yfpHY-8TY8JSpEMrSmGya8927l492-mKQdm8HWTkfFxoxPznTa9GvVuF4N680ROqhVE8zx-3mIHn5d3i-u0-Xd1c3i5zLVVIg81aTKclzqUmQq44xVhchzIJUhvOQFFYbGxcqMamB1WXGFVa04n8KMCAB6iC62uv1YtqbSsVGvGtl72yq_kU5Z-W-ks2u5ci-SZZQyEFHgx7uAd8-jCYNsbdCmaVRn3BgkLqAgBDIoInq6hz660cffDJLQjFCgAnCkYEtp70Lwpt41g0FOM5X7M40pJ58fsUv4mGAE0i0Q1Mr8rfpfwVch1aru</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Salmen, A.</creator><creator>von Ahsen, N.</creator><creator>Trampe, A.K.</creator><creator>Hoepner, R.</creator><creator>Plavina, T.</creator><creator>Subramanyam, M.</creator><creator>Kuesters, G.</creator><creator>Gold, R.</creator><creator>Chan, A.</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201601</creationdate><title>Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy</title><author>Salmen, A. ; von Ahsen, N. ; Trampe, A.K. ; Hoepner, R. ; Plavina, T. ; Subramanyam, M. ; Kuesters, G. ; Gold, R. ; Chan, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3778-c2d481bcb74a4655d978802de26b6937e3e3e5b43c05fbd6a1afa66e26b527003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Encephalitis</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>Risk assessment</topic><topic>Short Report</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salmen, A.</creatorcontrib><creatorcontrib>von Ahsen, N.</creatorcontrib><creatorcontrib>Trampe, A.K.</creatorcontrib><creatorcontrib>Hoepner, R.</creatorcontrib><creatorcontrib>Plavina, T.</creatorcontrib><creatorcontrib>Subramanyam, M.</creatorcontrib><creatorcontrib>Kuesters, G.</creatorcontrib><creatorcontrib>Gold, R.</creatorcontrib><creatorcontrib>Chan, A.</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis journal - experimental, translational and clinical</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salmen, A.</au><au>von Ahsen, N.</au><au>Trampe, A.K.</au><au>Hoepner, R.</au><au>Plavina, T.</au><au>Subramanyam, M.</au><au>Kuesters, G.</au><au>Gold, R.</au><au>Chan, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy</atitle><jtitle>Multiple sclerosis journal - experimental, translational and clinical</jtitle><addtitle>Mult Scler J Exp Transl Clin</addtitle><date>2016-01</date><risdate>2016</risdate><volume>2</volume><spage>2055217316630008</spage><epage>2055217316630008</epage><pages>2055217316630008-2055217316630008</pages><issn>2055-2173</issn><eissn>2055-2173</eissn><abstract>Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2–2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8–17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1–3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0–3.4), n = 298, p = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3–90.4) increased PML risk (p = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>28607714</pmid><doi>10.1177/2055217316630008</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2055-2173 |
| ispartof | Multiple sclerosis journal - experimental, translational and clinical, 2016-01, Vol.2, p.2055217316630008-2055217316630008 |
| issn | 2055-2173 2055-2173 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5433507 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Encephalitis Immunotherapy Monoclonal antibodies Risk assessment Short Report Viral infections |
| title | Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T16%3A06%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20analyses%20of%20anti-JCV%20antibody%20index%20for%20risk%20assessment%20of%20progressive%20multifocal%20leukoencephalopathy&rft.jtitle=Multiple%20sclerosis%20journal%20-%20experimental,%20translational%20and%20clinical&rft.au=Salmen,%20A.&rft.date=2016-01&rft.volume=2&rft.spage=2055217316630008&rft.epage=2055217316630008&rft.pages=2055217316630008-2055217316630008&rft.issn=2055-2173&rft.eissn=2055-2173&rft_id=info:doi/10.1177/2055217316630008&rft_dat=%3Cproquest_pubme%3E1909220409%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2342303701&rft_id=info:pmid/28607714&rft_sage_id=10.1177_2055217316630008&rfr_iscdi=true |